UndisclosedStrategic acquisitionTechnologyCompleted
OpenAI acquires drug development AI startup Orchestra Bio
OpenAI has acquired Orchestra Bio, a startup whose AI agents monitor studies, track finances and resolve clinical trial scheduling problems for pharmaceutical teams. Orchestra's staff and technology will join OpenAI's Rosalind life sciences unit. Terms were not disclosed.
Why it matters: The deal bolsters OpenAI's Rosalind life sciences unit, which works with drugmakers including Novo Nordisk and Moderna.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Get tech deals like this every morning
The day's biggest deals in five minutes. Free, with no paywalled links.